| Previous close | 228.00 |
| Open | 228.00 |
| Bid | 210.50 |
| Ask | 220.50 |
| Strike | 440.00 |
| Expiry date | 2024-01-19 |
| Day's range | 114.64 - 228.00 |
| Contract range | N/A |
| Volume | |
| Open interest | N/A |
- Business Wire
GRAIL CCGA Discovery Results Published in Cancer Cell Reveal Methylation as Promising DNA Hallmark for Multi-Cancer Early Detection
MENLO PARK, Calif., November 17, 2022--GRAIL, LLC, a healthcare company whose mission is to detect cancer early when it can be cured, today announced findings from a fundamental substudy of the Circulating Cell-free Genome Atlas (CCGA; NCT02889978) study, demonstrating that methylation had the most promising combination of cancer detection and prediction of cancer signal origin when compared with other evaluated approaches. This is the first rigorous and systematic comparison of various genomic
- Simply Wall St.
Illumina Third Quarter 2022 Earnings: EPS Misses Expectations
Illumina ( NASDAQ:ILMN ) Third Quarter 2022 Results Key Financial Results Revenue: US$1.12b (flat on 3Q 2021). Net...
- Zacks
Illumina (ILMN) Q3 Earnings Beat Estimates, '22 View Slashed
Delays in instruments and consumables purchases, negative foreign exchange impact and consumables inventory deleveraging are expected to impede growth in the rest of 2022 for Illumina (ILMN).
